Ryan Sullivan, MD

Ryan Sullivan, MD, explains how tumor infiltrating lymphocytes could impact the melanoma treatment landscape if approved by the FDA.

Ryan Sullivan, MD, discusses the 5-year data pooled from the phase III COMBI-d and COMBI-v trials, which each studied dabrafenib (Tafinlar) plus trametinib (Mekinist) in patients with&nbsp;<em>BRAF V600</em>&ndash;mutant unresectable or metastatic melanoma.